title: The use of the block cycle length as a safe and efficient means of interrupting sustained ventricular tachycardia and its pharmacological modification.
abstract: In nine patients who had inducible monomorphic sustained ventricular tachycardia (VT), rapid pacing was performed in 11 episodes of morphologically distinct VT at progressively shorter cycle lengths and VT was interrupted at a critical cycle length. The VT interrupting critical cycle length was defined as the block cycle length (BCL) and the effect of Class I antiarrhythmic drugs were examined. Both the VT cycle length (VTCL) and the BCL were prolonged after administration of either drug. The overall mean ratio of the BCL to the VTCL was unchanged after procainamide administration, but increased after the use of mexiletine. The ratio, however, varied in individual VTs and the BCL after treatment with Class I antiarrhythmic drugs could not be predicted from the ratio baseline value, although the ratio was always > 60% and the hazard of VT acceleration might be avoided if the BCL is used.
authors.affiliation: First Department of Internal Medicine, Niigata University School of Medicine, Asahimachi, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Ohira
authors.forename: S
authors.initials: S
authors.lastname: Niwano
authors.forename: H
authors.initials: H
authors.lastname: Furushima
authors.forename: K
authors.initials: K
authors.lastname: Taneda
authors.forename: M
authors.initials: M
authors.lastname: Chinushi
authors.forename: Y
authors.initials: Y
authors.lastname: Aizawa
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002037:Bundle-Branch Block / Q000503:physiopathology / Q000628:therapy*; D002304:Cardiac Pacing, Artificial; D003131:Combined Modality Therapy; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008801:Mexiletine / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D011342:Procainamide / Q000008:administration & dosage* / Q000009:adverse effects; D013611:Tachycardia, Atrioventricular Nodal Reentry / Q000503:physiopathology / Q000628:therapy; D017180:Tachycardia, Ventricular / Q000503:physiopathology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D008801:Mexiletine; D011342:Procainamide